An island in the Mediterranean is furthering diabetes research in New Jersey

June 8, 2015 by Lynda Rudolph
Lisa Denzin, left, is working with postdoctoral research fellow and former Sardinian graduate student Francesca Virdis, to understandthe role of DM in preventing the development of type 1 diabetes in humans." Credit: John Emerson

One look at Sardinia's white-sand beaches and turquoise water would lead you to assume that this part of the world is devoted entirely to idyllic getaways and sun-filled vacations. You'd never guess that the island's population is also contributing evidence to diabetes research in the United States. Geneticists from Sardinia – the second-largest island in the Mediterranean, with a population of a little more than one and a half million – are working with Lisa Denzin, and  associate professor of pediatrics at Rutgers Robert Wood Johnson Medical School and resident scientist, Child Health Institute of New Jersey, to understand the genetic underpinnings that trigger type 1 diabetes mellitus.

Why Sardinia?

Sardinians suffer from the world's second-highest rate of type 1  – one of the most common chronic childhood diseases, which results from an autoimmune destruction of insulin-producing beta cells. Since 1990, the Insulin-Dependent Diabetes Mellitus Sardinia Project has been investigating preclinical phases of in a large cohort of people. The goal is to learn why some people who are genetically at risk for type 1 diabetes don't develop the disease.

There's another reason Sardinia is the perfect location for this research. The island has proved to be a rich source of data mining for this and other projects because of its isolated population. It's simpler to investigate the environmental, immunological, and genetic factors related to the cause and development of diseases such as type 1 diabetes.

Understanding the disease

"Most autoimmune diseases' genetic susceptibility is linked to genes in the (MHC) called human leukocyte antigens (HLA)," says Dr. Denzin. The HLA genes control and regulate the immune system. "There are HLA class I and class II genes, and the class II genes have a stronger link to autoimmunity," she adds. Although 50 percent of genetic components are linked to HLA molecules, other genes in the MHC are also involved. "Because HLAs occur in so many different forms, the diversity makes them difficult to study in terms of autoimmune disease," says Denzin. The Sardinian team was interested in knowing if not only HLA class II genes but also other genes encoded within the MHC region were mediating protection from developing type 1 diabetes.

When the Italian geneticists mapped the genes further, they discovered that an allele of a gene encoding a protein that Dr. Denzin's laboratory works on – called DM – is associated with protection from type 1 diabetes. DM controls the presentation of HLA class II proteins at the cell surface – known to trigger immunity. Finding a specific allele of DM that is mediating protection from type 1 diabetes suggests that this allele – or version of DM – might in fact alter this process, thereby leading to protection.

Opening the door to collaboration

Dr. Denzin was approached by Sardinian researchers Francesco Cucca, a physician professor of medical genetics, University of Sassari, Italy, and director of the National Research Council of Italy's Institute of Genetic and Biomedical Research, and Valeria Orrú, permanent researcher, University of Cagliari, Italy. "We received an email from Dr. Orrú expressing an interest in our mouse model results – where we showed if we altered activity of the DM protein, we could protect a non-obese diabetic mouse for diabetes," says Dr. Denzin. "They suggested to us that modulating DM activity could be the mechanism by which the people in the Sardinian study are protected from type I diabetes."

The partnership of the labs was formalized when Francesca Virdis, a former Sardinian graduate student of Orrú's, became part of the project, working in Denzin's lab as a postdoctoral research fellow. Virdis's goal is to use biochemical and cell biological assays established in Dr. Denzin's lab to answer the question of altered activity. "If we can show that this DM has altered function, we could make a significant discovery in type 1 diabetes," says Denzin.

A potential druggable target for type 1 diabetes

"HLA class II and DM are needed to fight infection, so you can't simply get rid of them. What's important about this idea is that rather than trying to eliminate molecules, we simply change the way they function," says Dr. Denzin. "DM could be a druggable target. Potentially changing the way the molecule works might be enough." A protective genetic variant could lead to a useful treatment. "Usually people are looking for lots of things," says Denzin. "We're fortunate to be focusing on one specific molecule to find an answer.."

The data from these experiments represent steps toward understanding the role of DM in preventing the development of type 1 diabetes in humans.

Explore further: Specific trans fatty acids linked with incident diabetes

Related Stories

Specific trans fatty acids linked with incident diabetes

May 28, 2015
(HealthDay)—Among older adults, specific trans fatty acids (TFAs) may be associated with diabetes mellitus (DM), according to a study published in the June issue of Diabetes Care.

Genetically elevated triglyceride level associated with protection against type 2 diabetes

May 28, 2015
Elevated plasma triglyceride level is considered a risk factor for type-2 diabetes, but new findings suggest that a genetically-elevated triglyceride level is associated with protection against type-2 diabetes. Yann Klimentidis, ...

Increased risk for head, neck cancers in patients with diabetes

July 24, 2014
Diabetes mellitus (DM) appears to increase the risk for head and neck cancer (HNC). Evidence suggests certain cancers are more common in people with DM, but the risk of HNC in patients with DM has not been well explored. ...

One in ten AMI patients have unrecognized incident diabetes

April 23, 2015
(HealthDay)—One in 10 acute myocardial infarction (AMI) patients without a previous diagnosis of diabetes mellitus (DM) have underlying DM, according to research published online April 21 in Circulation: Cardiovascular ...

New study challenges link between HLA class I hyperexpression in pancreas and type 1 diabetes

January 6, 2015
The cause of type 1 diabetes remains unknown. Several studies using immunohistochemistry (IHC) have independently reported hyperexpression of human leukocyte antigen (HLA) class I on pancreatic islet cells in young patients ...

Type 1 diabetes testing may be cheaper, faster

March 11, 2013
Work by researchers at The University of Western Australia could revolutionise testing for Type 1 diabetes around the world.

Recommended for you

Scientists discover a new way to treat type 2 diabetes

July 21, 2017
Medication currently being used to treat obesity is also proving to have significant health benefits for patients with type 2 diabetes. A new study published today in Molecular Metabolism explains how this therapeutic benefit ...

Alzheimer's drug cuts hallmark inflammation related to metabolic syndrome by 25 percent

July 20, 2017
An existing Alzheimer's medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the ...

Diabetes or its precursor affects 100 million Americans

July 19, 2017
Almost one-third of the US population—100 million people—either has diabetes or its precursor condition, known as pre-diabetes, said a government report Tuesday.

One virus may protect against type 1 diabetes, others may increase risk

July 11, 2017
Doctors can't predict who will develop type 1 diabetes, a chronic autoimmune disease in which the immune system destroys the cells needed to control blood-sugar levels, requiring daily insulin injections and continual monitoring.

Diabetes complications are a risk factor for repeat hospitalizations, study shows

July 7, 2017
For patients with diabetes, one reason for hospitalization and unplanned hospital readmission is severe dysglycemia (uncontrolled hyperglycemia - high blood sugar, or hypoglycemia - low blood sugar), says new research published ...

Researchers identify promising target to protect bone in patients with diabetes

July 7, 2017
Utilizing metabolomics research techniques, NYU Dentistry researchers investigated the underlying biochemical activity and signaling within the bone marrow of hyperglycemic mice with hopes of reducing fracture risks of diabetics

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

dobson_randy
not rated yet Jun 08, 2015
mgdanimals4, you are correct, but that is for TYPE 2 diabetes..they are talking about TYPE 1 which is a totally different thing.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.